Moderately Reduced Estimated Glomerular Filtration Rate (eGFR) among Community - Dwelling Older People Associated with Increased Long Term Mortality: A Study from Low to Middle Income Country in Asia.

Peenida Skulratanasak

Mahidol University Faculty of Medicine Siriraj Hospital <https://orcid.org/0000-0001-5171-508X>

Chalobol Chalernsri

Mahidol University Faculty of Medicine Siriraj Hospital

Wichai Aekplakorn

Mahidol University Faculty of Medicine Ramathibodi Hospital

Varalak Srinonprasert (✉ varalak.sri@mahidol.ac.th)

Faculty of Medicine Siriraj Hospital, Mahidol University

Research article

Keywords: Community-dwelling older population, Estimated glomerular filtration rate (eGFR), Fourth National Health Examination Survey, increased mortality, Thailand

Posted Date: November 19th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-66723/v2>

License: This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background: Reduced glomerular filtration rate (GFR) is regarded as a component of renal senescence; however, the full impact of chronic kidney disease (CKD) among older people is still not fully understood. This study aimed to investigate the effect of reduced GFR on all-cause mortality, and the combined effect of socioeconomic status and CKD on mortality among older Thai population.

Methods: A retrospective cohort of Thai population aged >60 years was enrolled from the Fourth National Health Examination Survey, and estimated GFR (eGFR) and comorbid disease data were collected. Mortality information was gathered from the National Civil Registration and Vital Statistics System. Factors associated with all-cause mortality were determined using Cox proportional hazards model.

Results: A total of 9,080 participants (mean age: 69.5 years) were included. Prevalence of CKD stage 3-5 was 53.3%. During the 2008-2015 period, the overall mortality rate among CKD was 28.9 per 1,000 person-years. The stages of CKD significantly associated with increased mortality were stages 3b, 4, and 5, as follows: HR: 1.4 (95% CI: 1.2-1.63), 2.2 (95% CI: 1.78-2.71), and HR: 5.9 (95% CI: 4.26-8.15), respectively. People with higher socioeconomic status and moderate-stage CKD had lower mortality than lower socioeconomic status moderate-stage CKD.

Conclusion: Moderate decline in eGFR was found to be independently associated with all-cause mortality in Thai elderly population. Socioeconomic disparities were also observed among older CKD. Implementation of a mass screening program to identify asymptomatic individuals would accelerate diagnosis and treatment, and this would reduce the costs of care associated with advanced-stage disease.

Background

Chronic kidney disease (CKD) is increasingly being recognized as a global health issue with a high burden of disease, particularly among low to middle income countries (LMICs)⁽¹⁾. The prevalence of CKD was reported to significantly increase with age due to the incremental effect of traditional risk factors for CKD; such as diabetes mellitus, hypertension, and cardiovascular diseases, among older people⁽²⁾. However, the prevalence of CKD in high income countries showed conflicting results. Recent studies from USA, England, Norway, and Korea demonstrated stable prevalence of CKD despite of transitions to the aging society^(3, 4), while another study reported an increasing trend⁽⁵⁾. On the other hand, a recent comprehensive review suggested that the prevalence and burden of CKD is expected to rise with rapid urbanization and the increasing prevalence of noncommunicable diseases in LMICs⁽⁶⁾.

The clinical significance of the new definition of CKD according to KDIGO 2012 Clinical Practice Guideline, has been an issue of debate for unnecessarily overdiagnosis of CKD, particularly for defining CKD among older people^(2, 7, 8). The guideline Previous study⁽⁹⁾ showed a lower risk of end-stage renal disease (ESRD) in older population compared to their younger counterparts because of the slow decline

in estimated GFR (eGFR). Moreover, early-stage CKD was shown to associate with lower mortality in older adults compared to younger adults with CKD.⁽¹⁰⁾ It has been suggested that the majority of older patients with CKD did not transition to ESRD, but that they died from other causes. Although the association between socioeconomic status and the prevalence of CKD is well established⁽¹¹⁾, the socioeconomic disparity in CKD with regard to mortality risk was demonstrated only in high income countries^(11, 12). Evidence specific to the clinical impact of CKD staging on mortality among older people in LMICs remains comparatively scarce.

Thailand is a middle-income country with an increasing prevalence of cardiometabolic diseases. This trend during the last decade is supported by data from recent national health examination surveys⁽¹³⁻¹⁵⁾. Increases in related risk factors and the average age of the population suggest an increasing prevalence of CKD in Thailand. Previous studies from Thailand^(16, 17) reported a prevalence of CKD among older people of approximately 40%, which is substantially higher than the rate of CKD among younger population. However, those studies did not explore the impact of CKD on mortality among older population, and whether any identified association is influenced by socioeconomic status. Accordingly, the aim of this study was to investigate the effect of reduced GFR on all-cause mortality, and the combined effect of socioeconomic status and CKD on mortality among older persons in Thailand.

Methods

A retrospective cohort of elderly Thai population aged 60 years or more from the Fourth Thai National Health Examination Survey (NHES-IV) conducted during 2008-2009 were evaluated in 2016 to determine all-cause mortality. NHES-IV was a nationally representative survey using a multistage, stratified sampling of the Thai population for which the detailed of sampling methods have been described⁽¹⁴⁾. Briefly, the first stage of sampling units was provinces in each region in Thailand, the second stage was district in each province, the third was electoral unit (EUs) or villages, and, the last stage was age and gender-specific individuals. Medical comorbid disease (including eGFR), functional status, and socioeconomic status data were collected at the baseline assessment in NHES-IV. The vital status of each participant was ascertained from the National Civil Registration and Vital Statistics System.

Data collection and measurement

Serum creatinine was measured using modified Jaffe method. Estimated glomerular filtration rate was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation⁽¹⁸⁾. In this study, CKD was defined according to GFR category by Kidney Disease: Improving Global Outcomes (KDIGO) staging, as follows: G1, G2, G3a, G3b, G4 and G5 as GFR ≥ 60 (G1 + G2), 45-59, 30-44, 15-29, and <15 ml/min/1.73m², respectively.⁽¹⁹⁾ Reduced GFR was defined as GFR less than 60 ml/min/1.73m². In the present study, stages 3-5 CKD were classified as moderately to severely decreased GFR.

Diabetes was defined as fasting plasma glucose of >7.0 mmol/L, diagnosis by a physician, or taking antidiabetic medications.⁽²⁰⁾ Hypertension was defined as systolic blood pressure ≥ 140 mmHg, diastolic blood pressure ≥ 90 mmHg, or history of using any antihypertensive medications. Hypercholesterolemia was defined as total serum cholesterol >5.2 mmol/L or use of cholesterol-lowering medication within the previous 2 weeks. According to WHO criteria, anemia was defined as hemoglobin level <13 g/dl in males, and <12 gm/dl in females⁽²¹⁾.

Data collected in the NHES-IV, including demographic, socioeconomic, and health data such as smoking history, medication used, and common medical conditions, using semi-structured interview with standardized questionnaires. Medical comorbidities inquired in the interview included history of diabetes, hypertension, high cholesterol, asthma, chronic airway disease, allergy and cerebrovascular disease. Data relating to activities of daily living (ADLs) for both basic ADLs (B-ADLs) and instrumental ADLs (I-ADLs) were also obtained by interviewing enrolled participants and relatives. Impairment in ADLs was defined as the requirement for any assistance in performing ADL-related tasks, which included feeding, dressing, bathing, toileting and transferring from beds or chairs. I-ADL impairment was defined as the requirement for any assistance in complex tasks including using telephone, handling finances, responsibility for own medication, using transportation or driving and housework. The wealth index score was determined by assessing the number of household items owned, and then a standardized score was assigned to each participant⁽²²⁾. Socioeconomic status (SES) was stratified into 5 quintiles, with the lowest quintile indicating the poorest group, and the highest quintile indicating the wealthiest group.

Mortality data was retrieved until May 2016 from the Thai Vital Registration System, Bureau of Registration Administration, Ministry of Interior, which was affirmed to be a reliable source of death statistic in Thailand.⁽²³⁾

Statistical analysis

Descriptive statistics were used to compare baseline characteristics of participants. Categorical data are reported as frequency and proportion, and continuous data are given as mean $\pm$ standard deviation or median with minimum and maximum depending on the distribution of data. Analysis of variance (ANOVA) test was applied for continuous variables, while chi-square test was used for categorical variables. A p -value less than 0.05 was considered statistically significant. In order to consider for the multistage, stratified sampling survey design of the NHES-IV, the analysis was carried out by using svyset syntax to adjusted for all stage of sampling and finite population correction. The adjusted data was saved for further analysis. Cox regressions were conducted to determine the unadjusted hazard ratios (HRs) for mortality. Potential confounders of all-cause mortality among participants with CKD included in the analysis were age, gender, current smoking status, regular analgesic use, hypertension, diabetes, hypercholesterolemia, history of stroke, anemia, and wealth index score. Variables that had a $p < 0.1$ in univariate analyses were then included in a Cox proportional hazards model. Statistical analyses were performed using STATA 15.0 (StataCorp LP, College Station, TX, USA).

Results

Patient demographic data and prevalence of CKD

A total of 9,080 participants with a mean age of 69.5 ± 7.0 years were included. The mean age of patients with CKD stage 3-5 was higher than that of people without CKD. The prevalence of CKD stage 3-5 in this cohort was 53.3%, and the prevalence of CKD by stage was 34.0%, 14.5%, 4.0%, and 0.8% for stage 3a, 3b, 4, and 5, respectively. The prevalence of CKD stage 3-5 increased with age, as follows: 44.2% for age group 60-69, 61.2% for age group 70-79, and 76.3% for age group 80 years or more. Comorbid diseases including diabetes, hypertension, hypercholesterolemia, anemia and stroke, were reported at an increasingly higher proportion as the stages of CKD becoming more advanced. Baseline characteristics of participants by CKD stage based on GFR category are shown in Table 1.

Estimated GFR decreased with increasing age, particularly among participants with diabetes mellitus and/or hypertension. Further analysis was conducted among participants aged 85 years or older without diabetes and hypertension, and the mean eGFR was $53.4 \text{ ml/min/1.73m}^2$, which corresponds with CKD stage 3 according to the current guideline.

Mortality and CKD staging

During a total follow-up time of 52,120.8 person-years, 1,505 (15.3%) participants died for an overall mortality rate of 28.9 per 1,000 person-years (95% confidence interval [CI]: 27.5-30.4). Among CKD subjects, the mortality rate increased with more advanced stage of CKD from 27.2 per 1,000 person-years (95% CI: 24.9-29.7) in CKD stage 3a to 167.3 per 1,000 person-years (95% CI: 124.1-225.6) in CKD stage 5 (Table 2). Survival curves compared among the different stages of CKD are illustrated in Figure 1.

Factors associated with increased mortality

The factors associated with all-cause mortality from univariate and multivariable analyses are shown in Table 3. In univariate analysis, age, male, hypertension, diabetes, hypercholesterolemia, stroke, anemia, smoking, regular used analgesic drugs and all stages of CKD were significantly associated with increased mortality risk. Better socioeconomic status was shown to be a protective factor against mortality. Subsequent multivariate analysis revealed age, male, diabetes, hypercholesterolemia, stroke, anemia, smoking and regular used analgesic drugs to be independent risk factors for mortality. CKD stages 3b to stages 5 were also independently associated with increased risk of mortality in a dose-response manner, as follows: hazard ratio [HR]:

HR: 1.4 (95% CI: 1.2-1.63) for stage 3b; HR: 2.2 (95% CI: 1.78-2.71) for stage 4; and, HR: 5.9 (95% CI: 4.26-8.15) for CKD stage 5. Our analysis also showed socioeconomic status to be independently associated with mortality. Specifically, the higher the wealth index, the lower the person's risk of death.

Discussion

The present study demonstrates CKD to be an important risk factor for increased mortality among older people, and the strongest association with mortality is among patients with advanced-stage CKD. Three studies have explored the effect of CKD on mortality among community-dwelling older people⁽²⁴⁻²⁶⁾, and all of those studies were conducted in high income countries. CKD was identified as an independent risk factor for mortality in two of those studies^(24, 26), but not in the one other study⁽²⁵⁾. The present study confirms that CKD plays an important role in predicting mortality among older people in a middle-income country, and that relationship was shown to be statistically significant starting at CKD stage 3b and higher. The observed associations were in a dose-response manner, with stronger associations observed as the stage of CKD became higher. The observed association between CKD and mortality among the elderly is consistent with recently reported findings that older people with CKD showed higher metabolic complications, cognitive impairment, frailty, and all-cause mortality.^(27, 28)

A key reason for changing the definition of CKD stemmed from reported evidence suggesting association between reduced eGFR and increased risk of death^(7, 29). However, when we specifically focused on older population at an eGFR level of 60 ml/min/1.73m², which is consistent with CKD stage 3a, the association with mortality was fairly weak in younger older people, and non-significant in people aged older than 75 years. Nevertheless, this association become more apparent at lower levels of eGFR⁽²⁹⁾. The present study also found a similar trend that lower eGFR, starting at CKD stage 3b, is associated with increased mortality. Our finding is also consistent with that from a previous study⁽³⁰⁾ that found CKD stage 3b to be significantly associated with increased mortality. This finding has important clinical implications for managing older people with multiple chronic comorbidities. Inaccurate diagnosis or staging of CKD would result in extra psychological concern for the patient, and the burden and costs of repeated assessment and potentially unnecessary treatment⁽⁷⁾. However, failure to identify and treat a disease would likely lead to increased morbidity and premature death. Our finding that CKD stage 3b-5 is clinically significant in older adults should heighten our attention to the need for an improved pathway of care for these patients.

Regarding the relationship between socioeconomic status and mortality among older people with CKD, the present study found the socioeconomic status of people in the 2 highest wealth quintiles to be significantly correlated with lower all-cause mortality among participants with CKD stage 3b or higher in both univariate and multivariate analysis. Lower socioeconomic status is well recognized for its association with higher prevalence of unfavorable outcomes of CKD in high income countries^(11, 12). Evidence specific to the effect of disparities in socioeconomic status on CKD patients in low to middle income countries is limited, particularly relative to the association between socioeconomic status and clinical outcomes⁽¹¹⁾. The present study demonstrated association between lower socioeconomic status and clinical disadvantages among patients with CKD stage 3b-5 in a middle-income country setting, which is similar to the findings in high income countries. Association between socioeconomic status and CKD might be due to the fact that non-communicable diseases (NCDs), chronic inflammation, neurohormonal activation, and oxidative stress are all more prevalently observed among people with a lower socioeconomic status⁽¹²⁾. Moreover, lower socioeconomic status may also be associated with

limited access to healthcare services and substandard living conditions that contribute to the development of CKD, disease progression, and premature mortality⁽¹²⁾.

Limitations

This study has some mentionable limitations. First, the fact that CKD was defined via one-time serum creatinine testing without urine albumin level testing could cast some doubt over the true prevalence of CKD in our study population. However, the fact that CKD stage 3b, stage 4, and stage 5 were found to be strongly associated with increased mortality in multivariate analysis demonstrates the validity and clinical importance of the method used in our study. Second and last, we did not evaluate data specific to the progression of CKD to ESRD. This evolution is complicated by the fact that older people may die from other causes before developing and/or succumbing to ESRD. Understanding this course after adjusting for related confounders would further improve our understanding of the relationship between CKD and mortality among older population. The strengths of this study include the large size of the study population and the fact that sampling was nationwide. Moreover, representative sampling of community-dwelling older persons was employed to estimate the prevalence of the condition. Our study also explored the association between CKD and all-cause mortality in a low to middle income country. Although a number of studies have investigated the prevalence of CKD, no studies have evaluated the impact of CKD on clinical outcomes in a low to middle income country⁽¹⁾.

Conclusion

Moderate decline in eGFR was found to be independently associated with all-cause mortality in community-dwelling elderly Thai population. Socioeconomic disparities were also observed among older CKD, with higher mortality observed among poorer people. Implementation of a mass screening program to identify asymptomatic individuals would accelerate diagnosis and treatment, and this would reduce the costs of care associated with advanced-stage disease.

Abbreviations

ADLs: Activities of daily living

ANOVA: Analysis of variance

BMI: Body mass index

B-ADLs: Basic activities of daily living

CI: Confidence interval

CKD: Chronic kidney disease

CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration

eGFR: Estimated glomerular filtration rate

ESRD: End stage renal disease

GFR: Glomerular filtration rate

HR: Hazard ratio

I-ADLs: Instrumental activities of daily living

KDIGO: Kidney Disease: Improving Global Outcomes

LMICs: Low to middle income countries

NCD: Non-communicable disease

NHES-IV: Fourth Thai National Health Examination Survey

Ref: Reference

SD: Standard deviation

SES: Socioeconomic status

Declarations

Ethics Approval and Consent to Participate

The study was approved by Institutional Review Board, Siriraj hospital, Mahidol University. All participants had signed the informed consents before included in this study.

Consent for publication

Not applicable.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare no competing interests.

Funding

No funding was obtained for this study.

Authors' contributions

Affiliations:

Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

P. Skulratanasak and V. Srinonprasert

Department of Preventive and Social Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

C. Chalerm Sri

Department of Community Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

W. Aekplakorn

Authors' contributions

All authors have participated in the conceptualization and design of the study. CC and VS analyzed data and all authors interpret the data. PS wrote the first version of the manuscript. VS and WA revised the manuscript for intellectual content. All authors critically revised and approved the final manuscript and accepted the final submitted version.

Corresponding author

Correspondence to V. Srinonprasert

Acknowledgements

The authors gratefully acknowledge the Thai National Health Examination Survey IV that was supported by the Health Systems Research Institute; Bureau of Policy and Strategy, Ministry of Public Health; Thai Health Promotion Foundation; and The National Health Security Office, Thailand. The current study was approved by Faculty of Medicine Siriraj Hospital, Mahidol University.

References

1. Mills KT, Xu Y, Zhang W, Bundy JD, Chen CS, Kelly TN, et al. A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010. *Kidney Int.* 2015;88(5):950-7.
2. Levey AS, Inker LA, Coresh J. Chronic Kidney Disease in Older People. *JAMA.* 2015;314(6):557-8.
3. Hsu RK, Powe NR. Recent trends in the prevalence of chronic kidney disease: not the same old song. *Curr Opin Nephrol Hypertens.* 2017;26(3):187-96.

4. Murphy D, McCulloch CE, Lin F, Banerjee T, Bragg-Gresham JL, Eberhardt MS, et al. Trends in Prevalence of Chronic Kidney Disease in the United States. *Ann Intern Med.* 2016;165(7):473-81.
5. Bowling CB, Sharma P, Fox CS, O'Hare AM, Muntner P. Prevalence of reduced estimated glomerular filtration rate among the oldest old from 1988-1994 through 2005-2010. *Jama.* 2013;310(12):1284-6.
6. Stanifer JW, Muir A, Jafar TH, Patel UD. Chronic kidney disease in low- and middle-income countries. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.* 2016;31(6):868-74.
7. Moynihan R, Glasscock R, Doust J. Chronic kidney disease controversy: how expanding definitions are unnecessarily labelling many people as diseased. *Bmj.* 2013;347:f4298.
8. McClure M, Jorna T, Wilkinson L, Taylor J. Elderly patients with chronic kidney disease: do they really need referral to the nephrology clinic? *Clinical kidney journal.* 2017;10(5):698-702.
9. O'Hare AM, Choi AI, Bertenthal D, Bacchetti P, Garg AX, Kaufman JS, et al. Age affects outcomes in chronic kidney disease. *J Am Soc Nephrol.* 2007;18(10):2758-65.
10. O'Hare AM, Bertenthal D, Covinsky KE, Landefeld CS, Sen S, Mehta K, et al. Mortality risk stratification in chronic kidney disease: one size for all ages? *J Am Soc Nephrol.* 2006;17(3):846-53.
11. Zeng X, Liu J, Tao S, Hong HG, Li Y, Fu P. Associations between socioeconomic status and chronic kidney disease: a meta-analysis. *J Epidemiol Community Health.* 2018;72(4):270-9.
12. Nicholas SB, Kalantar-Zadeh K, Norris KC. Socioeconomic disparities in chronic kidney disease. *Adv Chronic Kidney Dis.* 2015;22(1):6-15.
13. Aekplakorn W, Abbott-Klafter J, Premgamone A, Dhanamun B, Chaikittiporn C, Chongsuvivatwong V, et al. Prevalence and management of diabetes and associated risk factors by regions of Thailand: Third National Health Examination Survey 2004. *Diabetes Care.* 2007;30(8):2007-12.
14. Aekplakorn W, Chariyalertsak S, Kessomboon P, Sangthong R, Inthawong R, Putwatana P, et al. Prevalence and management of diabetes and metabolic risk factors in Thai adults: the Thai National Health Examination Survey IV, 2009. *Diabetes Care.* 2011;34(9):1980-5.
15. Deerochanawong C, Ferrario A. Diabetes management in Thailand: a literature review of the burden, costs, and outcomes. *Global Health.* 2013;9:11.
16. Ong-Ajyooth L, Vareesangthip K, Khonputsu P, Aekplakorn W. Prevalence of chronic kidney disease in Thai adults: a national health survey. *BMC nephrology.* 2009;10:35-.
17. Ingsathit A, Thakkestian A, Chaiprasert A, Sangthawan P, Gojaseni P, Kiattisunthorn K, et al. Prevalence and risk factors of chronic kidney disease in the Thai adult population: Thai SEEK study. *Nephrol Dial Transplant.* 2010;25(5):1567-75.
18. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. *Ann Intern Med.* 2009;150(9):604-12.
19. Eknoyan G LN, Eckardt K-U, et al. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney Int Suppl.* 2013;3:1-150.

20. Aekplakorn W, Chariyalertsak S, Kessomboon P, Sangthong R, Inthawong R, Putwatana P, et al. Prevalence and management of diabetes and metabolic risk factors in Thai adults: the Thai National Health Examination Survey IV, 2009. *Diabetes Care*. 2011;34(9):1980-5.
21. Nutritional anaemias. Report of a WHO scientific group. *World Health Organ Tech Rep Ser*. 1968;405:5-37.
22. Aekplakorn W, Satheannoppakao W, Putwatana P, Taneepanichskul S, Kessomboon P, Chongsuvivatwong V, et al. Dietary pattern and metabolic syndrome in Thai adults. *J Nutr Metab*. 2015;2015:468759.
23. Tangcharoensathien V, Faramnuayphol P, Teokul W, Bundhamcharoen K, Wibulpholprasert S. A critical assessment of mortality statistics in Thailand: potential for improvements. *Bull World Health Organ*. 2006;84(3):233-8.
24. Roderick PJ, Atkins RJ, Smeeth L, Mylne A, Nitsch DD, Hubbard RB, et al. CKD and mortality risk in older people: a community-based population study in the United Kingdom. *Am J Kidney Dis*. 2009;53(6):950-60.
25. Hirani V, Naganathan V, Blyth F, Le Couteur DG, Gnjdic D, Stanaway FF, et al. Multiple, but not traditional risk factors predict mortality in older people: the Concord Health and Ageing in Men Project. *Age (Dordrecht, Netherlands)*. 2014;36(6):9732-.
26. Fried LP, Kronmal RA, Newman AB, Bild DE, Mittelmark MB, Polak JF, et al. Risk Factors for 5-Year Mortality in Older Adults The Cardiovascular Health Study. *JAMA*. 1998;279(8):585-92.
27. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. *Lancet*. 2010;375(9731):2073-81.
28. Drawz PE, Babineau DC, Rahman M. Metabolic complications in elderly adults with chronic kidney disease. *J Am Geriatr Soc*. 2012;60(2):310-5.
29. Hallan SI, Matsushita K, Sang Y, Mahmoodi BK, Black C, Ishani A, et al. Age and Association of Kidney Measures With Mortality and End-stage Renal Disease Kidney Measures and Mortality and ESRD by Age. *JAMA*. 2012;308(22):2349-60.
30. Fox CS, Matsushita K, Woodward M, Bilo HJ, Chalmers J, Heerspink HJ, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. *Lancet*. 2012;380(9854):1662-73.

Tables

Table 1. Baseline characteristics of participants by CKD stage based on GFR category

Characteristics	All	No CKD and stage 1+2 ^a n (%)	CKD stage 3a ^b n (%)	CKD stage 3b ^c n (%)	CKD stage 4 ^d n (%)	CKD stage 5 ^e n (%)	<i>p</i>
Participants	9,080	4,242 (46.7)	3,087 (34.0)	1,321 (14.5)	359 (4.0)	71 (0.8)	
Age (yrs), mean±SD	69.5±7.0	67.7±6.3	70.1±7.1	72.6±7.3	73.2±7.0	72.3±7.4	<0.001
Gender	4,455 (49.1)	2,171 (51.2)	1,459 (48.4)	603 (45.7)	149 (41.5)	37 (52.1)	<0.001
Current smoking	1,740 (19.2)	964 (22.7)	522 (16.9)	205 (15.5)	39 (10.9)	10 (14.1)	<0.001
Regular use of analgesic medication	2,796 (30.9)	1,303 (30.8)	920 (30.0)	427 (32.4)	122 (34.1)	24 (33.8)	0.005
Systolic blood pressure (mmHg)	3,037 (33.5)	1,015 (24.0)	1,116 (36.2)	656 (49.8)	212 (59.1)	38 (53.5)	<0.001
Diabetes	1,466 (16.6)	507 (12.3)	488 (16.3)	317 (24.7)	128 (36.5)	26 (37.7)	<0.001
Hypercholesterolemia	5,998 (66.1)	2,740 (64.6)	2,110 (68.4)	877 (66.4)	231 (64.4)	40 (56.3)	0.005
Stroke	326 (3.6)	126 (3.0)	116 (3.8)	61 (4.6)	19 (5.3)	4 (5.6)	0.007
Heart failure	3,477 (39.1)	1,327 (31.9)	1,132 (37.5)	704 (54.5)	251 (71.9)	63 (90.0)	<0.001
Health index							0.21
ntile 1	1,023 (20.8)	816 (19.2)	617 (20.0)	288 (21.8)	80 (22.3)	22 (31.0)	
ntile 2	1,552 (17.1)	713 (16.8)	538 (17.4)	234 (17.7)	56 (15.6)	11 (15.5)	
ntile 3	1,034 (20.2)	887 (20.9)	595 (19.3)	261 (19.8)	80 (22.3)	11 (15.5)	
ntile 4	1,750 (19.3)	806 (19.0)	602 (19.5)	262 (19.8)	67 (18.6)	13 (18.3)	
ntile 5	2121 (23.4)	1020 (24.0)	735 (23.8)	276 (20.9)	76 (21.2)	14 (19.7)	

A *p*-value<0.05 indicates statistical significance

^aNo CKD and stage 1+2 = eGFR >60 ml/min/1.73 m²

^bCKD stage 3a = eGFR 45-59 ml/min/1.73 m²

^cCKD stage 3b = eGFR 30-44 ml/min/1.73 m²

^dCKD stage 4 = eGFR 15-29 ml/min/1.73 m²

^eCKD stage 5 = eGFR <15 ml/min/1.73 m²

Abbreviations: CKD, chronic kidney disease; GFR, glomerular filtration rate; SD, standard deviation; B-ADL, basic activities of daily living; I-ADL, instrumental activities of daily living

Table 2. Mortality rate by eGFR group during the 2008-2015 study period

CKD staging classified by eGFR	N at risk	Person-years of follow-up	Deaths during follow-up	Mortality per 1,000 person-years (95% CI)
All	9,080	52,120.8	1,505	28.9 (27.5-30.4)
No CKD and CKD stage 1+2	4,242	24,917.4	525	21.1 (19.3-23.0)
Stage 3a	3,087	13,837.2	485	27.2 (24.9-29.7)
Stage 3b	1,321	7,272.7	317	43.6 (39.0-48.7)
Stage 4	359	1,836.6	135	73.5 (62.1-87.0)
Stage 5	71	257.0	43	167.3 (124.1-225.6)

Abbreviations: eGFR, estimated glomerular filtration rate; CKD, chronic kidney disease; CI, confidence interval

Table 3. Hazard ratios of factors significantly associated with all-cause mortality in older persons

Factors	Univariate analysis		Multivariable analysis	
	HR (95% CI)	p-value	HR (95% CI)	p-value
Age (per one year)	1.08 (1.07-1.09)	<0.001*	1.07 (1.07-1.08)	<0.001*
Gender (female)	0.7 (0.63-0.77)	<0.001*	0.67 (0.6-0.75)	<0.001*
Hypertension	1.16 (1.04-1.28)	0.007*	0.96 (0.86-1.08)	0.5
Diabetes	1.34 (1.18-1.53)	<0.001*	1.43 (1.25-1.64)	<0.001*
Hypercholesterolemia	0.7 (0.63-0.77)	<0.001*	0.85 (0.76-0.94)	0.003*
Stroke	2.41 (1.99-2.92)	<0.001*	2.14 (1.76-2.61)	<0.001*
Anemia	1.67 (1.51-1.84)	<0.001*	1.15 (1.03-1.29)	0.011*
Smoking	1.26 (1.11-1.42)	<0.001*	1.16 (1.01-1.32)	0.034*
Regular used analgesic drugs	1.16 (1.03-1.29)	0.007*	1.16 (1.03-1.28)	0.012*
Wealth index				
Quintile 1	1 (Ref)		1 (Ref)	
Quintile 2	0.88 (0.75-1.02)	0.097	0.92 (0.79-1.08)	0.32
Quintile 3	0.82 (0.71-0.95)	0.008*	0.86 (0.74-1.00)	0.06
Quintile 4	0.68 (0.58-0.8)	<0.001*	0.71 (0.6-0.84)	<0.001*
Quintile 5	0.59 (0.5-0.69)	<0.001*	0.66 (0.56-0.78)	<0.001*
CKD based on GFR category				
Stage 1+2	1 (Ref)		1 (Ref)	
Stage 3a	1.29 (1.14-1.46)	<0.001*	1.07 (0.94-1.22)	0.29
Stage 3b	2.09 (1.82-2.4)	<0.001*	1.4 (1.2-1.63)	<0.001*
Stage 4	3.57 (2.95-4.31)	<0.001*	2.2 (1.78-2.71)	<0.001*
Stage 5	8.45 (6.19-11.5)	<0.001*	5.9 (4.26-8.15)	<0.001*

A p -value<0.05 indicates statistical significance
*Adjusted for age, gender, hypertension, diabetes, hypercholesterolemia, history of stroke, anemia, current smoking status, regular analgesic use and wealth index score
Abbreviations: HR, hazard ratio; CI, confidence interval; Ref., reference; CKD, chronic kidney disease; GFR, glomerular filtration rate

Figures

Figure 1

Survival curves compared among the different stages of chronic kidney disease (CKD)

Figure 1

Survival curves compared among the different stages of chronic kidney disease (CKD)